We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NTRK

News List

FDA Approves Vitrakvi for Solid Tumors with NTRK Gene Fusions americanpharmaceuticalreview
November 29, 2018
The Food and Drug Administration (FDA) has granted accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology and Bayer) for adult and pediatric patients with .....
FDA approves first oral TRK inhibitor with Loxo Oncology's Vitrakvi pharmafile
November 28, 2018
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), for the treatment of solid tumours
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor fda
November 28, 2018
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

Previous page 1 2 Next page